RXi Pharmaceuticals Corp. (RXII) Partners with EyeGate to Advance Ocular Treatment Technology

QualityStocks would like to highlight RXi Pharmaceuticals (NASDAQ: RXII), a recognized leader in RNAi-based therapeutic discovery and development, with a comprehensive therapeutic platform that includes both RNA interference (RNAi) compounds and delivery methods. The company is leveraging this broad and integrated RNAi therapeutic platform to build a pipeline of RNAi therapeutics for the treatment of a number of disease areas, including its core focus of developing treatments for anti-scarring and retinal disorders as well as a continued interest in oncology and indications accessible by spinal cord delivery.

In the company’s news yesterday,

RXi Pharmaceuticals Corp. announced its partnership with EyeGate Pharma, a leader in non-invasive ocular drug delivery, to collaborate on the ocular delivery of RNAi therapeutics.

Per the agreement, both companies will contribute technology, expertise, and resources to develop ocular treatments.

“The development of RNAi therapeutics to treat retinal disorders is a key focus for our company, and we are excited to be collaborating with EyeGate to explore new, patient friendly approaches for delivering RNAi therapeutics to the eye,” Noah D. Beerman, president and CEO of RXi stated in the press release. “In pre-clinical studies, our sd-rxRNA™ (or self-delivering rxRNA™) compounds have shown effective gene silencing in the retina following intraocular injection. Combining our RNAi technology with EyeGate’s unique, non-invasive ocular delivery system (EyeGate® II), provides us with the potential opportunity to develop novel treatments for many ocular diseases and to improve treatment options.”

The companies’ collaborative efforts will use EyeGate’s iontophoresis technology to deliver RXi’s sd-rxRNA compounds to the eye in preclinical models. EyeGate’s iontophoresis drug delivery method drives low-level electrical currents to administer a drug across the ocular surface of the eye. From here, the companies said they believe RXi’s sd-rxRNA compounds will enter the retinal cells and thwart disease causing genes.

Stephen From, president and CEO of EyeGate, said its partnership with RXi mirrors EyeGate’s mission to expand applications and market presence for its technology.

“Collaborating with RXi reflects our strategy to commercialize innovative products for the ophthalmology community. EyeGate is developing a unique ocular Delivery System, the EyeGate II, which is a non-invasive drug delivery technology that eliminates ocular injections and the risks associated with them. Our collaboration with RXi will enable us to expand the drug delivery options for the EyeGate II Delivery System into RNAi therapeutics, developing new uses and markets for the device, as well as developing more patient friendly treatments for retinal disease based on RXi’s sd-rxRNA technology,” From stated.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.